Fenspiride

Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

Product Specifications

CAS Number

[5053-06-5]

UNSPSC

12352005

Hazard Statement

H302-H361-H412

Target

Histamine Receptor; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fenspiride.html

Solubility

10 mM in DMSO

Smiles

O=C1OC2(CCN(CCC3=CC=CC=C3)CC2)CN1

Molecular Formula

C15H20N2O2

Molecular Weight

260.33

Precautions

P264-P270-P273-P280-P330-P405-P501

References & Citations

[1]Matuszewska A, et al. Long-term administration of fenspiride has no negative impact on bone mineral density and bone turnover in young growing rats. Adv Clin Exp Med. 2019 Jun;28 (6) :771-776.|[2]Cortijo J, et al. Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study. Eur J Pharmacol. 1998 Jan 2;341 (1) :79-86.|[3]De Castro CM, et al. Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia. Eur J Pharmacol. 1995 Dec 29;294 (2-3) :669-76.